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Abstract
ARTS (Sept4_i2) is a mitochondrial pro-apoptotic protein that functions as a tumor suppressor. Its expression is significantly
reduced in leukemia and lymphoma patients. ARTS binds and inhibits XIAP (X-linked Inhibitor of Apoptosis protein) by
interacting with its Bir3 domain. ARTS promotes degradation of XIAP through the proteasome pathway. By doing so, ARTS
removes XIAP inhibition of caspases and enables apoptosis to proceed. ARTS contains 27 unique residues in its C-terminal
domain (CTD, residues 248–274) which are important for XIAP binding. Here we characterized the molecular details of this
interaction. Biophysical and computational methods were used to show that the ARTS CTD is intrinsically disordered under
physiological conditions. Direct binding of ARTS CTD to Bir3 was demonstrated using NMR and fluorescence spectroscopy.
The Bir3 interacting region in ARTS CTD was mapped to ARTS residues 266–274, which are the nine C-terminal residues in
the protein. Alanine scan of ARTS 266–274 showed the importance of several residues for Bir3 binding, with His268 and
Cys273 contributing the most. Adding a reducing agent prevented binding to Bir3. A dimer of ARTS 266–274 formed by
oxidation of the Cys residues into a disulfide bond bound with similar affinity and was probably required for the interaction
with Bir3. The detailed analysis of the ARTS – Bir3 interaction provides the basis for setting it as a target for anti cancer drug
design: It will enable the development of compounds that mimic ARTS CTD, remove IAPs inhibition of caspases, and
thereby induce apoptosis.
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Introduction
Apoptosis, programmed cell death, is a key cellular process.
Impaired apoptosis may lead to cancer [1]. Induction of cancer
cell apoptosis is the essence of current anti-cancer treatments such
as radiation and chemotherapy. Thus, pro- and anti-apoptotic
proteins may serve as targets for anti cancer drug design based on
molecular specificity.
Intrinsically disordered proteins (IDPs) or regions (IDRs) in
proteins lack stable tertiary structures under physiological condi-
tions [2,3,4]. IDRs usually exist in an ensemble of extended and
highly flexible, dynamically interchanging conformations. These
conformations may exclude or include certain elements of
secondary structure giving rise to various levels of disorder [4,5].
Such elements may be implied by the appearance of residual
structure, which may serve as a basis for induced conformation
upon binding [5,6,7]. The flexible chain and transient conforma-
tions of the IDRs are advantageous in molecular recognition,
enabling high specificity and low affinity resulting in specific but
easily reversed interactions [3,8]. Various intrinsically disordered
proteinsareinvolved innumeroushumandiseases,includingcancer
[9,10,11]. IDPs are attractive targets for drugs that are designed to
interfere with protein-protein interactions [12,13,14,15].
ARTS (Apoptosis-Related protein in the TGF-beta Signaling
pathway) is a pro-apoptotic mitochondrial protein and a unique
member of the septin family, which functions as a tumor suppressor
[16,17]. ARTS expression is lost in more than 70% of acute
lymphoblastic leukemia patients [18]. ARTS promotes apoptosis
throughbindingand inhibitingInhibitorof Apoptosis(IAP) proteins
and specifically XIAP (X-linked IAP) [19,20]. ARTS binding to
XIAP promotes caspase activation [19]. ARTS-induced-de-repres-
sion and activation of caspases occurs through increased protea-
some mediated degradation of XIAP [19,21]. ARTS was recently
shown to initiate the mitochondrial apoptotic pathway upstream of
the Cytochrome C and SMAC proteins [20]. The ARTS-XIAP
complex is formed immediately after induction of apoptosis,
significantly before the release of SMAC and Cytochrome C from
the mitochondria [20]. All IAP proteins contain at least one
baculoviral IAP repeat (BIR) domain. BIR domains can directly
interact with caspases and inhibit their apoptotic activity [22,23].
XIAP is considered to be the most potent inhibitor of caspases in
vitro, and elevated levels of this protein are found in human tumors
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24655[24,25,26]. ARTS specifically binds to the Bir3 domain in XIAP
[20]. Deletion of the ARTS/Sept4 gene in mice promotes
spontaneous development of tumors as a result of impaired
apoptosis of stem and progenitor cells [27]. The surviving stem
cells express increased levels of XIAP. The apoptosis, stem cell and
tumor phenotypes of Sept4/ARTS-null mice are suppressed by
inactivation of XIAP, demonstrating that ARTS acts mainly by
targeting XIAP in vivo [27]. In addition to ARTS, mammalian
XIAP antagonists have been identified, including SMAC [28,29]
and Omi/HtrA2 [30,31]. SMAC and Omi contain a short,
conserved IAP Binding Motif (IBM), used for Bir3 binding
[28,29,32]. This motif is lacking in the ARTS sequence. The N-
terminal 10 residues of SMAC, which include the IBM, did not
display electron density in the unbound Smac crystal structure and
were thus suggested to be disordered in the unbound state [33].
ARTS/Sept4_i2 is a 30.8 kDa protein of 274 residues derived
by alternative splicing from the Septin 4 gene [16,34]. Thus,
ARTS shares most of its sequence with other isoforms of the Sept4
gene. Domain characterization of Sept4 [35,36] describes three
major domains including the N-terminal domain (residues 1–119),
a GTPase domain (residues 144–416) and a C-terminal domain
(residues 417–478) in addition to a poly-basic linker (residues 120–
143). Schematic representation of ARTS domains based on its
alignment with the sequence of the longest isoform Sep4_i1 is
presented in Figure 1. ARTS is missing 20 N-terminal residues
found in Sept4_i1, reducing the size of its N-terminal domain
(NTD, residues 1–100). The subsequent 24 residues form the
polybasic linker (PB, residues 101–124), similar to Sept4_i1. ARTS
contains a truncated form of the GTPase domain (t-GTPase,
residues 125–247) including the first 123 out of 273 residues of the
original GTPase domain in spet4_i1 [35]. The remaining 27
residues in ARTS C-terminal domain (CTD, residues 248–274)
constitute a unique sequence not found in any other Sept4
isoforms or other human septins. The unique C-terminus of
ARTS plays an important role in the pro-apoptotic function of
ARTS [19,36]. A truncated version of ARTS lacking 68 residues
from its C-terminal part (including the unique 27 residues in
ARTS) lost its ability to bind XIAP [19].
Herewepresentadetailed quantitativeanalysisofthestructure of
ARTS CTD and its interaction with Bir3. We show that ARTS
CTD is an intrinsically disordered region, which binds directly to
Bir3. NMR and CD spectra of ARTS CTD showed the pattern of
an IDR, in agreement with disorder predictions. Direct binding of
ARTS CTD to Bir3 was demonstrated using NMR and
fluorescence spectroscopy. The Bir3 interacting region in ARTS
CTD was mapped to ARTS residues 266–274, which are the nine
C-terminal residues in the protein. Alanine scan of ARTS 266–274
showed that His268 and Cys273 have the highest contribution to
Bir3 binding. Addition of a reducing agent caused abrogation of the
binding to Bir3. A dimer of ARTS 266–274, formed by oxidation of
the Cys residues into a disulfide bond, bound Bir3 with a similar
affinity as the monomer. We suggest that a dimer/oligomer of
ARTS may be needed for the interaction with Bir3. The detailed
analysis of the ARTS– Bir3 interaction providesthe basis for setting
it as a target for anti cancer drug design: It will enable the
development of compounds that mimic ARTS CTD, remove IAPs
inhibition of caspases, and thereby induce apoptosis.
Results
The CTD of ARTS is predicted to be disordered
The sequence of the ARTS protein was submitted to 18 publicly
available servers for protein disorder prediction (Figure 2A). In all
cases, the full-length ARTS sequence (274 residues) was submitted
and default parameters were used. Two regions were predicted to
be mainly disordered: the N-terminus (residues 1–105) and the C-
terminus (residues 250–274). The N-terminal domain of Sept4 (the
common sequence between isoform 1 and 4) has already been
suggested to be intrinsically disordered [35]. Residues 105–250 are
predicted to be almost completely ordered. A statistical analysis of
the residues in the CTD that are predicted to be disordered among
the 18 servers is presented in Figure 2B. This presentation
indicates that the major disordered region is located at the C-
terminal section of the CTD, mainly between residues 260–274.
The CTD sequence was analyzed for the content of order\di-
sorder promoting residues (Figure 2C): 66.7% of the residues are
disorder promoting (E, K, R, G, Q, S, P and A) and only 22.2%
are order-promoting (I, L, V, W, F, Y and C). 11.1% are neutral
residues.
A peptide derived from the C-terminal domain of ARTS is
intrinsically disordered: CD and NMR studies
The structural properties of the ARTS C-terminal domain
(CTD, residues 248–274) were studied using CD and NMR
spectroscopy. The far-UV CD spectrum of ARTS CTD in 20 mM
phosphate buffer, pH 7.4, at 20uC (Figure 3A) is composed largely
of a minimum at 200 nm and is missing the typical signatures of
secondary structures, indicating mainly a random coil. This is a
characteristic pattern for disordered regions. Calculating the
secondary structure content of ARTS CTD using the DichroWeb
server [37,38] indicated a high content of disordered regions
corresponding to 48% of the total secondary structured elements
(Helix 2%, Strand 31%, Turns 17%, data not shown). Changes of
the signal at 222 nm as a function of temperature from 10uCt o
Figure 1. Schematic representation of ARTS domains. The domain structure of ARTS/Sept4_12 is based on its alignment with the sequence of
the longer isoform Sep4_i1. The domains are: N-terminal domain, NTD, residues 1–100; polybasic linker, PB, residues 101–124; truncated GTPase
domain, t-GTPase, residues 125–247; and the C-terminal domain, CTD, residues 248–274. The P-loop motif is also annotated, residues 132–139.
doi:10.1371/journal.pone.0024655.g001
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temperature (Figure 3B). This indicates an apparent temperature-
induced formation of residual secondary structure. This set of CD
spectra also revealed a well-defined isodichroic point at 207 nm,
which may represent equilibrium among the unordered confor-
mations and the induced conformation. Calculation of the changes
in secondary structure content as a function of the temperature
using DichroWeb showed that the fraction of the disordered
structures decreased upon increasing the temperature from 49% at
10uC to 33% at 50uC. The
1H-NMR spectra of ARTS CTD
showed a narrow dispersion of amide resonances, ranging from
8.75–7.95 ppm, D=0.80 ppm. This pattern implies a random coil
conformation and is characteristic of disordered regions and
peptides, where residues are not held in a defined structure [39]
(Figure 3C).
Quantification of the interaction between the ARTS CTD
and Bir3
Fluorescence anisotropy was used to characterize the interaction
between ARTS CTD and the Bir3 subunit of XIAP. ARTS CTD
(residues 248–274) was synthesized using standard Fmoc chemistry
and labeled with fluorescein at its N-terminus. The Bir3 subunit of
Figure 2. Intrinsic disorder predictions of ARTS CTD. A: Disorder predictions for the full length ARTS sequence were done using 18 algorithms
in publicly available servers. B: Disorder prediction per residue in the CTD residues 248–274. Intrinsic disorder is predicted to increase towards the C-
terminus. C: Distribution of order- and disorder-promoting residues in the sequence of ARTS CTD. The residues are classified as order promoting (I, L,
V, W, F, Y, and C), disorder promoting (E, K, R, G, Q, S, P, and A) and neutral (all the others).
doi:10.1371/journal.pone.0024655.g002
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C-terminus and purified (see materials and methods and Figure
S1). The binding experiments were done in 20 mM Hepes buffer,
pH 7.4, 45 mM NaCl, at 10uC. Bir3 was titrated into fl-ARTS
CTD and the data were fit to 1:1 binding model resulting in
Kd=8.060.7 mM (Figure 4A). Addition of a reducing agent
(2 mM DTT) severely impaired the interaction between ARTS
CTD and Bir3 (Figure 4A).
Mapping of the ARTS CTD residues that mediate its
interaction with Bir3
NMR analysis of the Bir3-bound versus unbound ARTS CTD
was used to reveal the ARTS residues that mediate its interaction
with Bir3, which itself was too large to be seen in the spectra. The
TOCSY spectra were assigned using the NOESY spectra and then
compared. Figure 4B and C shows the overlay of the TOCSY
spectra of the free (red) and Bir3-bound (green) ARTS CTD. The
deviations of backbone Ha and HN proton chemical shifts upon
Bir3 binding are shown in Figure 4D. The overall dispersion of
amide resonances in the Bir3-bound state remained narrow,
indicating that there was no major structural change in the overall
conformation of ARTS CTD upon Bir3 binding. Changes in the
chemical shifts of specific residues in ARTS CTD indicate a
change in their chemical environment in the presence of Bir3. This
indicates the involvement of these residues in the interaction. The
residues in the C-terminal part of ARTS CTD underwent the
largest changes in chemical shift upon binding Bir3. His268 and
Cys 273 showed the largest chemical shift changes: The HIS268
peak showed a significant chemical shift change while the Cys273
peak almost completely disappeared in the presence of Bir3. An
alternative Cys peak corresponding to the newly bound confor-
mation was absent. The intensity of the His274 peak also
decreased, though to a lesser extent. In this case, a different peak
was present in the bound state. The His274 peak as well as the
peaks of E267, Q269, G270 and G272 also showed significant
chemical shift changes upon binding Bir3. Residues 248–266 did
not show significant chemical shift changes upon binding Bir3,
indicating they are not involved in the interaction. Thus, the Bir3
Figure 3. Secondary structure analysis of ARTS CTD. A: Far UV CD spectrum of ARTS CTD in phosphate buffer, pH 7.4 at 20uC and an ionic
strength of 50 mM. The strong absorption at 200 nm indicates a pattern of unfolded region, where a-helices or b-strands characteristic are absent. B:
The effect of temperature on the CD spectrum of ARTS CTD. All experiments were performed in 20 mM phosphate buffer, pH 7.4 at 20uC and an ionic
strength of 50 mM. Peptide concentration was 60 mM. The temperature range was 10–90uC. A linear increase of the CD signal at 222 nm as a function
of temperature is consistent with an apparent temperature-induced formation of a residual structure. C: The
1H-NMR spectrum of ARTS CTD in 90%
20 mM deuterated Hepes buffer and10% D2O, pH 6.8, at 15uC, ionic strength of 50 mM. The resonances have a narrow dispersion, as expected for an
unstructured polypeptide. The fingerprint resonances range between 8.75–7.95 ppm, D=0.80 ppm.
doi:10.1371/journal.pone.0024655.g003
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residues of ARTS.
Based on the NMR results, we divided ARTS CTD 248–274
into three non-overlapping peptides that covered its entire
sequence: ARTS 248–256, ARTS 257–265 and ARTS 266–274
(Table 1). The peptides were synthesized and labeled with
fluorescein and their binding to Bir3 was studied by fluorescence
anisotropy. Only fl-ARTS 266–274, derived from the nine
C-terminal residues of the protein, bound Bir3 with Kd=
2.560.3 mM. The peptides derived from ARTS 248–265 did
not show any binding (Figure 5A), in agreement with the NMR
results.
Figure 4. Quantitative analysis of the interaction between ARTS CTD and Bir3. A: Binding of ARTS CTD to Bir3. Bir3 was titrated into
fluorescein- labeled ARTS CTD 248–274 (purple) resulting in Kd=8.060.7 mM. Titration of Bir3 in the presence of 2 mM DTT resulted in no significant
binding (green). B and C: NMR TOCSY spectra of free ARTS CTD (red) and bir3 – bound ARTS CTD (green) show backbone amide chemical shift
deviations upon binding. B: Finger print resonances and C: enlargement. D: NMR mapping of the ARTS residues that mediate its binding to Bir3.
Shown are the chemical shift changes of ARTS CTD upon interaction with Bir3. The interacting ARTS residues are within the nine C-terminal residues.
The largest changes are displayed by residues E267, H268, Q269, C273 and H274.
doi:10.1371/journal.pone.0024655.g004
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ARTS residue to Bir3 binding we performed an alanine scan of
ARTS 266–274. A series of fluorescein labeled peptides were
synthesized based on the sequence of ARTS 266–274. In each
peptide one residue was replaced by alanine. The binding affinity
of the alanine-substituted peptides to Bir3 was determined by
fluorescence anisotropy (Figure 5B and C, Table 1). ARTS 266–
274 H268A and Cys273A did not bind Bir3. The alanine scan
results are in agreement with the NMR results, corroborating the
role of His268 and Cys273 in the interaction with Bir3.
ARTS CTD needs to be dimeric to bind Bir3
The importance of Cys273 residue for Bir3 binding raised the
question of whether disulfide bond formation is involved in the
interaction with Bir3. Addition of a reducing agent weakened the
interaction between the ARTS derived peptides and Bir3
(Figure 4A). This raised the possibility that a disulfide bond is
formed between two ARTS peptide molecules to form an active
dimer. To test this, a covalent dimer of ARTS 266–274 was
prepared by forming a disulfide bond between the Cys273 residues
of two peptide monomers. MS gave a single peak corresponding
the mass of the dimer (data not shown). Formation of the disulfide
bond was further supported by NMR, where a single set of peaks
was observed in which the Ha proton peaks of Cys273 were split
into two different peaks, representing two different orientations of
the hydrogens on the Cys273 Cb carbon (Figure 6A, B). Changes
in the chemical shift of the sequentially following His274 and
preceding Gln272 were also observed. Binding of Bir3 to the
dimeric fl-ARTS 266–274 was studied using fluorescence
spectroscopy (Fig. 6C). The results were fit to the Hill equation
resulting in Kd=2.460.1 mM and a Hill coefficient of 1.560.1.
These results suggest that one dimer of ARTS266–274 is capable
of binding at least two molecules of Bir3 in a cooperative manner
and indicates binding of a mixed monomer-dimer population to
Bir3. The apparent averaged Kd deduced from the best fit to Hill
model is similar to ARTS 266–274 monomer binding to Bir3.
These results imply that ARTS CTD may bind Bir3 as a dimer
and Cys 273 may be important for the dimerization of the CTD
and not necessarily for direct binding to Bir3.
To confirm its oligomeric state, ARTS CTD 248–274 was
analyzed by analytical gel filtration. The identities of all the peaks
were verified by mass spectrometry (Figure S2). In the presence of
2 mM DTT, ARTS CTD eluted from the gel filtration column as
a single peak that corresponded to the mass of the monomer. In
the absence of DTT an additional peak of mixed dimer and
monomer eluted earlier.
Discussion
Using structural and biophysical methods, we showed that the
nine C-terminal residues (266–274) of the proapoptotic ARTS
protein mediate its interaction with the Bir3 domain of XIAP.
These residues are in the unique C-terminal domain of ARTS.
The far-UV CD and NMR spectra of ARTS CTD indicated that
the CTD is disordered and lacks significant secondary structure
elements. The increase of the CD signal at 222 nm with increasing
temperature, as well as the isodichroic point, indicate a
conformational equilibrium between two states. This pattern
implies the possible existence of a temperature induced residual
structure, a common property of IDPs [7,40]. The residual
structure may serve as a starting point for an induced specific
conformation of the CTD upon interacting with binding partners
such as Bir3. The Bir3 binding residues in SMAC are also located
in a disordered terminal region. This may indicate a role for
terminal disordered residues in Bir3 inhibition.
Detailed mapping of the ARTS residues that mediate its
binding to Bir3 showed that His268 and Cys273 have the largest
contribution to the interaction. His268 showed the largest
deviation of NMR chemical shift upon Bir3 binding, while the
NMR peak of Cys273 almost completely disappeared in the
presence of Bir3. Mutating these residues to alanine abolished the
interaction with Bir3. Cys273 may have a role in ARTS CTD
dimerization and not only in direct binding to Bir3. This was
demonstrated by inhibition of the ARTS CTD-Bir3 interaction by
a reducing agent. Furthermore, the disulfide dimeric ARTS 266–
274, in which the disulfide bond was formed specifically between
the Cys273 residues of the two monomers, bound tightly to Bir3
with a Hill coefficient of 1.5, indicating binding of a mixed
monomer-dimer population to Bir3. This indicates that each
ARTS CTD monomer is able to bind one Bir3 subunit. Dimer
formation may also explain the disappearance of the Cys273 peak
from the NMR TOCSY spectrum upon addition of Bir3.
Formation of a disulfide bond between the Cys273 residues may
impose geometric strain on this region, enabling increased
exchange of amide protons that results in disappearance of the
signal. The single set of peaks, together with the high NMR sample
concentration, suggests that the predominant form was dimeric.
We conclude that dimer formation of ARTS CTD may be
important for its interaction with Bir3.
XIAP and other proteins from the IAP family are attractive
targets for anti-cancer drug design due to their elevated expression
in cancer cells and their association to chemo-resistance [25,41].
XIAP also contributes to metastasis formation in vivo [42]. The
most common small molecule IAP antagonists are mimetics of
endogenous IAP inhibitors such as SMAC/DIABLO, and some of
them are currently undergoing phase I and II clinical trials
[41,43]. ARTS was shown to function as a tumor suppressor
protein both in human and mice studies [18,27]. Furthermore, the
Table 1. ARTS CTD derived peptides: sequences and binding
affinity to Bir3.
Peptide name Sequence Kd (mM)
fl-ARTS 248–274 YGPSLRLLAPPGAVKGTGQEHQGQGCH 8.060.7
fl-ARTS 248–256 YGPSLRLLA nb
fl-ARTS 257–265 PPGAVKGTG nb
fl-ARTS 266–274 QEHQGQGCH 2.560.3
Dimer fl-ARTS
266–274
QEHQGQGCH(S-S)HCGQGQHEQ 2.4060.02
fl-ARTS 266–274
Q266A
AEHQGQGCH 0.960.1
fl-ARTS 266–274
E267A
QAHQGQGCH 3.660.8
fl-ARTS 266–274
H268A
QEAQGQGCH nb
fl-ARTS 266–274
Q269A
QEHAGQGCH 1.060.3
fl-ARTS 266–274
Q271A
QEHQGAGCH 1.360.2
fl-ARTS 266–274
C273A
QEHQGQGAHn b
fl-ARTS 266–274
H274A
QEHQGQGCA 0.860.3
nb, no binding detected. Alanine substitutions are indicated in bold.
doi:10.1371/journal.pone.0024655.t001
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mice were suppressed by inactivation of XIAP, demonstrating that
ARTS acts mainly by targeting XIAP in vivo [27]. Understanding
the ARTS – Bir3 interaction at the molecular level is essential for
developing peptides and small molecules based on the ARTS
CTD that would be able to inhibit XIAP. Future studies are
required to determine the ARTS binding sites on Bir3. Our results
lay the molecular basis for designing a new set of anti-IAPs lead
compounds that mimic the ARTS function, inhibit IAPs and
promote apoptosis of cancer cells.
Materials and Methods
Peptide synthesis, labeling and purification
ARTS derived peptides were synthesized using standard SPPS
methods on a Liberty Microwave-Assisted Peptide Synthesizer
(CEM) using standard Fmoc (9-fluorenylmethoxycarbonyl) chem-
istry as described [44]. The peptides were labeled using 59 and 69
carboxyfluorescein succinimidyl ester (Molecular Probes, Carls-
bad, CA) at their N terminus, as described in [45]. The peptides
were purified on a Gilson high-pressure liquid chromatography
using a reverse-phase C8 semi-preparative column (ACE) with
varying gradients of acetonitrile in water (both containing 0.001%
(v/v) trifluoroacetic acid). The peptides were analyzed by mass
spectrometry (Voyager DE-PRO, applied biosystems). Oxidation
of the labeled and unlabeled ARTS 266–274 was carried out
manually in solution after HPLC purification of the parent
peptide. The peptide (,0.5 mg/ml) was dissolved in DMSO and
diluted to 20% DMSO in 5% aqueous acetic acid. The pH was
adjusted to 6. The reaction was performed overnight with mild
shaking [46]. The peptides were purified again after the oxidation
reaction.
BIR3 expression and purification
The pET-21b(+) vector containing XIAP (252–350) Bir3
domain with a C-terminal His Tag was transformed into E. coli
strain BL21 Star
+ (DE3) (Novagen). Cells were grown at 37uCi n
LB medium to an optical density (600 nm) of ,0.6 and induced
with 0.4 mM isopropyl-b-D-1-thiogalactoside (IPTG). Cells were
harvested after 8 h of incubation at 37uC and were lysed by
Microfluidizer (Microfluidics). The protein was purified on
HiTrap nickel-Sepharose FF column (100610 mm, GE Health-
care), using an FPLC system (A ´KTA explorer, Amersham
Biosciences). The eluted protein was further purified by filtration
on a Sephacryl S100 column (950626 mm; Amersham Biosci-
ences). The protein was stored in 20 mM Hepes pH 7.4, 50 mM
NaCl, 10 mM bME, 0.02% sodium azide and was dialyzed before
experimental use.
Circular dichroism
CD spectra were recorded using a J-810 spectropolarimeter
(Jasco) in 25 mM potassium phosphate buffer, pH 7.3, 120 mM
KCl and 20 mM ARTS CTD 248–274, in a 0.1 cm quartz cuvette
for far-UV CD spectroscopy. Far-UV CD spectra were collected
over a spectral range of 185 nm to 260 nm. Data was collected
Figure 5. Alanine scan of ARTS CTD. A: Fluorescence anisotropy
binding studies of Bir3 and peptides derived from ARTS CTD: only ARTS
266–274 bound Bir3, with a Kd of 2.960.3 mM, while ARTS 248–256 and
ARTS 257–265 did not. B and C: Alanine scan of ARTS CTD 266–274:
binding studies using fluorescence anisotropy. Substituting H268 and
C273 by alanine impaired the binding of ARTS CTD to Bir3, while alanine
substitutions of Q266, E267, Q269 and Q271 mutations to Bir3 did not
affect binding. Binding affinities are given in Table 1.
doi:10.1371/journal.pone.0024655.g005
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experiment the peptide was centrifuged at 13,200 rpm for 5 min.
Wavelength scans were corrected for buffer contributions and
converted to molar ellipticity. Changes in the CD spectra were
monitored as a function of temperature from 10uCt o9 0 uC with
10uC steps, as described above. The molar ellipticity at 222 nm
was fit to a linear model. The secondary structure content was
calculated using DichroWeb [37,38] with the CDSSTR analysis
algorithm.
Analytical gel filtration
Analytical gel filtration of purified ARTS CTD 248–274 was
performed on an A ¨KTA Explorer (GE Healthcare- Amersham
Pharmacia, Giles, U.K.) using a Superose 30 analytical column
3061 cm (GE Healthcare) equilibrated with 20 mM Hepes buffer,
pH 7.4 and 50 mM NaCl. ARTS CTD concentrations of, 1–
2 mM were tested. ARTS CTD eluted with a flow rate of 1 ml/
min at 4uC and the elution profile was recorded by continuously
monitoring the UV absorbance at 220 nm. The eluted peaks were
analyzed for their molecular weight using mass spectrometry.
NMR
ARTS CTD derived peptides in lyophilized form were dissolved
in an aqueous solution (0.5–1.5 mM) of 20 mM deuterated -Hepes
buffer, 45 mM potassium chloride (Aldrich) and 0.02% (w/v)
sodium azide. Bir3 was dialyzed overnight against the deuterated
Hepes buffer prior to the experiment. The apparent pH was
adjusted to 6.860.2 with NaOH and the sample was centrifuged.
Figure 6. Dimer formation by the ARTS CTD peptide. A and B: NMR analysis of the oxidized versus non-oxidized ARTS 266–274. Overlay of the
TOCSY spectra of the fingerprint region (A) showing splitting of the Hb Cys273 into two signals, coupled with deviation of the chemical shift (B)o f
the neighboring residues H274, G 272 and Q271. C: Binding of the dimeric fl-ARTS 266–274 to Bir3 using fluorescence spectroscopy. D: Analytical size
exclusion chromatography of ARTS CTD with (Blue) and without (red) 2 mM DTT. In the absence of a reducing agent a second peak of ARTS dimer
was present.
doi:10.1371/journal.pone.0024655.g006
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found to be the optimal temperature for maximal conformational
stability without broadening. The instrument was a Bruker Avance
600 MHz DMX spectrometer, with a 5-mm selective probe
equipped with a self-shielded xyz-gradient coil. TOCSY [47],
COSY [48] and NOESY [49] spectra measured under identical
experimental conditions were used for resonance assignment,
using the sequential assignment methodology [50]. Spectra were
processed and analyzed with the TopSpin (Bruker Analytische
Messtechnik GmbH) and SPARKY (T. D. Goddard and D. G.
Kneller, SPARKY 3; University of California, San Francisco
http://www.cgl.ucsf.edu/home/sparky/). Chemical shifts devia-
tions of ARTS CTD in the Bir3 bound and unbound were
calculated from the TOCSY spectra using SPARKY.
Binding studies using fluorescence spectroscopy
Measurements were performed at 10uC by using a PerkinElmer
LS-50b luminescence spectrofluorimeter equipped with a Hamil-
ton microlabM dispenser as described in [44]. The fluorescently
labeled peptide concentrations were determined by using a UV
spectrophotometer (Shimadzu, Kyoto, Japan). The fluorescein-
labeled ARTS derived peptides were dissolved in 20 mM Hepes
buffer, pH 7.4 and 45 mM NaCl. 1 ml of the labeled peptide
solution was placed in a cuvette, and the non-labeled Bir3 (200 ml,
150 mM) was placed in the dispenser. Additions of 5 ml were
titrated at 90 sec intervals, the solution was stirred for 15 sec, and
the fluorescence and anisotropy were measured after each addition
by using an excitation wavelength of 480 nm and an emission
wavelength of 530 nm. Dissociation constants (Kd) were calculated
by fitting the fluorescence titration curves (corrected for dilution)
or fluorescence anisotropy curves to 1:1 binding model using
KALEIDAGRAPH (Synergy Software, Reading, PA). The
following equation was used for the single-site model of the
fluorescence results:
F~F0z
DF  ½ Bir3 
½Bir3 zKd
Where, F0 is the initial fluorescence, DF is the amplitude of the
fluorescence change from unbound and bound states, Kd is the
dissociation constant and [Bir3] is the added concentration of Bir3
domain. A similar equation was used to fit the anisotropy results by
replacing the fluorescence (F) with anisotropy (R) changes.
The Hill equation was used for fitting the binding of Bir3 to the
dimeric fl-ARTS 266–274 peptide:
F~F0z
DF   (Kn
a  ½ Bir3 
n)
1zKn
a  ½ Bir3 
n
Where, F0 is the initial fluorescence, DF is the amplitude of the
fluorescence change from unbound and bound states, Ka is the
association constant, [Bir3] is the added concentration of Bir3 and
n is the Hill coefficient.
Disorder predictions
The sequence of the full length ARTS (GenBank code:
AAG45673.1) was submitted to 10 publicly available servers
implementing 18 different algorithms for protein disorder
prediction. In all cases we used the default parameters. The
methods are reviewed in Ferron et al. [51].
Supporting Information
Figure S1 Bir3 expression and purification. The ex-
pressed Bir3 domain of XIAP (252–350) was purified in two steps:
A. Nickel affinity chromatography. Absorbance at 280 nm is
shown in red and the absorbance at 260 nm in blue. Addition of
the elution buffer containing 250 mM Imidazole is shown in green
line. Fraction numbers are indicated in red in the bottom of the
graph. Bir3 eluted around 30% elution buffer. B: SDS-PAGE of
the fractions indicates the presence of Bir3 in fractions 10–20.
Fractions 11–19 were collected for gel filtration purification. C:
Gel filtration chromatogram of Bir3 Absorbance at 280 nm is
shown in red and the absorbance at 260 nm in blue.. Bir3 eluted
in the main peak (fractions 7–11). D: SDS-PAGE of the main peak
fractions indicating the high purity of Bir3.
(TIF)
Figure S2 Mass Spectrum analysis of the analytical size
exclusion chromatography results. The mass spectrum of
two representative fractions from each of the peaks eluted from the
analytical gel filtration experiments: A. In the absence of a
reducing agent two different peaks eluted. The early fraction
included the mass of ARTS CTD monomer as well as dimer
whereas the later peak includes practically only the monomer. B.
In the presence of 2 mM DTT only one peak corresponding to the
monomer eluted from the column.
(TIF)
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